Why the study?
Does left atrial volume indexed to body surface area (LAVi) measured in mid ventricular diastasis by coronary computed tomographic angiography predict major adverse cardiac events?
Does left atrial volume indexed to body surface area (LAVi) measured in mid ventricular diastasis by coronary computed tomographic angiography predict major adverse cardiac events?
Left atrial volume indexed to body surface area measured in mid ventricular diastasis by coronary CTA is a significant independent predictor of major adverse cardiac events, providing incremental prognostic value.
May support incremental MACE risk stratification on coronary CTA; leaves open prospective validation before routine use.
PURPOSE: Previous studies have demonstrated that left atrial (LA) volume has incremental prognostic value in predicting major adverse cardiac events (MACE). However, the predictive ability of LA volume in mid diastasis has not been investigated. We determined the incremental predictive value of LA volume indexed to body surface area (LAVi) measured in mid ventricular diastasis. MATERIALS AND METHODS: A total of 96 patients with MACE (all-cause mortality and nonfatal myocardial infarction) were matched to 96 controls without adverse events on follow-up. Coronary computed tomographic angiography images were reconstructed at the 75% phase (mid ventricular diastasis). LA volumes were measured and indexed to the body surface area. The predictive value of LAVi was assessed using Cox proportional hazard models for the MACE. RESULTS: LAVi was significantly larger (P<0.001) in the cases with adverse clinical outcomes (63.8±2.1 mL/m) versus the controls (50.3±1.2 mL/m). In a multivariate analysis, both significant coronary artery disease (defined as >70% stenosis in at least 1 coronary artery) and LAVi emerged as significant predictors of MACE with P-values of 0.0022 and 0.0001, respectively. CONCLUSIONS: A significantly larger LAVi was associated with MACE. LAVi was an incremental predictor to traditional clinical variables for MACE. The assessment of LAVi may be considered during coronary computed tomographic angiography and could potentially be incorporated into risk stratification and decision-making strategies.
No takes yet. Share an insight, caveat, or question.
Boczar et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: